There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

In the Boston area, three months into the new year, the mood in the biotech industry has soured and the outlook has clouded.

Biogen and Sage Therapeutics' zuranolone has ... The biotech has another couple of recent approvals under its belt that have improved its outlook, however, including Aduhelm follow-up Leqembi ...

I'm Marc Goodman, one of the biopharma analyst, and we're lucky to have Biogen with us here, Alisha Alaimo, who is the President of North America. Thank you very much for joining us. Well ...

Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal. Specific details of the lawsuit are not yet available ...

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and safety of ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Pre-Market: 5:58:06 a.m. EDT Loading Chart for BIIB ...